242 related articles for article (PubMed ID: 10912950)
21. The mechanism of action of quinocarmycin citrate (KW 2152) on mouse L1210 cells in vitro.
Kanamaru R; Konishi Y; Ishioka C; Kakuta H; Sato T; Ishikawa A; Asamura M; Wakui A
Cancer Chemother Pharmacol; 1988; 22(3):197-200. PubMed ID: 3409454
[TBL] [Abstract][Full Text] [Related]
22. The effects of alpha-methylene-gamma-lactone purines and pyrimidines on L1210 lymphoid leukemia nucleic acid metabolism.
Hall IH; Lee KH
Anticancer Res; 1991; 11(1):337-42. PubMed ID: 2018369
[TBL] [Abstract][Full Text] [Related]
23. Tricyclic pyrone analogs: a new class of microtubule-disrupting anticancer drugs effective against murine leukemia cells in vitro.
Newell SW; Perchellet EM; Ladesich JB; Freeman JA; Chen Y; Liu L; Hua DH; Kraft SL; Basaraba RJ; Perchellet JP
Int J Oncol; 1998 Feb; 12(2):433-42. PubMed ID: 9458372
[TBL] [Abstract][Full Text] [Related]
24. Isolation and characterization of an L1210 cell line retaining the sodium-dependent carrier cif as its sole nucleoside transport activity.
Crawford CR; Ng CY; Belt JA
J Biol Chem; 1990 Aug; 265(23):13730-4. PubMed ID: 1974252
[TBL] [Abstract][Full Text] [Related]
25. Effect of derivatives of chrysophanol, a new type of potential antitumor agents of anthraquinone family, on growth and cell cycle of L1210 leukemic cells.
Darzynkiewicz Z; Carter SP; Kapuscinski J; Watanabe KA
Cancer Lett; 1989 Aug; 46(3):181-7. PubMed ID: 2766258
[TBL] [Abstract][Full Text] [Related]
26. The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity.
Jackson RC; Fry DW; Boritzki TJ; Roberts BJ; Hook KE; Leopold WR
Adv Enzyme Regul; 1985; 23():193-215. PubMed ID: 3840949
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxicity of ribo-and arabinoside boron nucleosides in tissue culture cells.
Sood A; Spielvogel BF; Powell WJ; Bastow KF; Miller MC; Hall IH
Anticancer Res; 1994; 14(4A):1483-8. PubMed ID: 7979174
[TBL] [Abstract][Full Text] [Related]
28. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene.
Bowden GT; Roberts R; Alberts DS; Peng YM; Garcia D
Cancer Res; 1985 Oct; 45(10):4915-20. PubMed ID: 4027978
[TBL] [Abstract][Full Text] [Related]
29. 5-hexyl-2'-deoxyuridine inhibition of nucleoside transport in L1210 cells.
Cory JG; Downes DL; Ng CY; Belt JA
Oncol Res; 1992; 4(4-5):175-9. PubMed ID: 1504377
[TBL] [Abstract][Full Text] [Related]
30. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
[TBL] [Abstract][Full Text] [Related]
31. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues.
Hsiang YH; Liu LF; Wall ME; Wani MC; Nicholas AW; Manikumar G; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Aug; 49(16):4385-9. PubMed ID: 2545341
[TBL] [Abstract][Full Text] [Related]
32. Modulation of thiol pools by vitamin K3 and its effect on survival of sensitive and resistant murine tumor cells.
Parekh H; Chavan S; Chitnis M
Anticancer Drugs; 1991 Apr; 2(2):159-68. PubMed ID: 1683589
[TBL] [Abstract][Full Text] [Related]
33. Anthracycline metabolites from baumycin-producing Streptomyces sp. D788. II. New anthracycline metabolites produced by a blocked mutant strain RPM-5.
Yoshimoto A; Fujii S; Johdo O; Kubo K; Nishida H; Okamoto R; Takeuchi T
J Antibiot (Tokyo); 1993 Jan; 46(1):56-64. PubMed ID: 8436560
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of folate analogue transport inward in L1210 cells during methotrexate therapy of leukemic mice: evidence of the nature of the effect, possible host mediation, and pharmacokinetic significance.
Sirotnak FM; Poser RE; Barrueco JR
Cancer Res; 1987 Oct; 47(20):5334-9. PubMed ID: 3498533
[TBL] [Abstract][Full Text] [Related]
35. Aclarubicin inhibits etoposide induced apoptosis through inhibition of RNA synthesis in P388 murine leukemic cells.
Nagata T; Higashigawa M; Shimono Y; Cao DC; Yan Mao X; M'soka T; Inamochi H; Hori H; Kawasaki H; Sakurai M
J Exp Clin Cancer Res; 1998 Dec; 17(4):435-42. PubMed ID: 10089064
[TBL] [Abstract][Full Text] [Related]
36. Comparative biochemical studies of adriamycin and daunomycin in leukemic cells.
Wang JJ; Chervinsky DS; Rosen JM
Cancer Res; 1972 Mar; 32(3):511-5. PubMed ID: 5061305
[No Abstract] [Full Text] [Related]
37. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia.
Meriwether WD; Bachur NR
Cancer Res; 1972 Jun; 32(6):1137-42. PubMed ID: 5030814
[No Abstract] [Full Text] [Related]
38. Antineoplastic activity of boron-containing thymidine nucleosides in Tmolt3 leukemic cells.
Hall IH; Hall ES; Chi LK; Shaw BR; Sood A; Spielvogel BF
Anticancer Res; 1992; 12(4):1091-7. PubMed ID: 1503401
[TBL] [Abstract][Full Text] [Related]
39. Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype.
Kamath N; Grabowski D; Ford J; Ganapathi R
Br J Cancer; 1993 Jun; 67(6):1203-8. PubMed ID: 8099806
[TBL] [Abstract][Full Text] [Related]
40. Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Lack of correlation between cellular doxorubicin levels and expression of resistance.
Ganapathi R; Grabowski D
Biochem Pharmacol; 1988 Jan; 37(2):185-93. PubMed ID: 3342075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
